Plain-English translation of NCT07805122 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new approach to managing side effects from cabozantinib, a medication used to treat advanced kidney cancer. The study will use blood tests, genetic testing, and careful monitoring of how your body handles the medication to personalize your dose and reduce unwanted side effects. The goal is to help you stay on this treatment at the right dose for as long as possible.
Many patients taking this medication experience side effects that are severe enough to interrupt treatment, reduce doses, or stop the drug entirely—which can make it less effective against cancer. This trial is testing whether personalized monitoring can help doctors adjust your dose more carefully, reducing side effects while keeping the treatment working to fight your cancer.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive your regular kidney cancer treatment (cabozantinib, with or without another medication). In addition, you will have frequent blood tests to measure how much medication is in your body and genetic testing to understand how your body processes the drug. Your doctor will use this information to adjust your dose if needed to reduce side effects while keeping your treatment effective. You will need to attend regular clinic visits for monitoring throughout your treatment.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
Italy